Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCLL.L Regulatory News (CLL)

  • There is currently no data for CLL

Pre-close trading update

22 Jul 2010 07:00

RNS Number : 7231P
Cello Group plc
22 July 2010
 



22 July 2010

 

Cello Group plc

 

Pre-close trading update

 

Cello Group (AIM: CLL, 'Cello', or 'the Group'), the leading independent market research and consulting group, publishes a trading update for the six months to 30 June 2010. Cello has continued to trade well and will show like for like income growth and double digit operating profit growth for the first half of the financial year.

 

The Group continues to experience growing income from its international blue chip client base, with particular growth arising from the US, where further organic investment is planned for the second half of the year. Income from UK clients has held up well, with several notable private sector wins, while as anticipated there are likely to be further declines in public sector income over the coming months.

 

The like for like income growth achieved, combined with a lower cost base as a result of pro-active action taken in 2009, are expected to lead to a healthy improvement in profitability in 2010.

 

Divisional trading

 

The Research and Consulting division continues to trade strongly, returning to like for like income growth. This has been driven by continued robustness in core client activity levels, most notably in pharmaceutical and health related sectors, as well as the growing international revenues.

 

The recent investments made to increase the Group's overseas capabilities have begun to bear fruit. Cello recently relocated its US business into a new office in New York. This will act as a resource hub for other Group brands as they continue to build their US client base.

 

New business activity has increased markedly, with notable major project wins from ITV, GSK, Visa Europe, 3M, AG Barr, BA, Expedia, Heineken, Mars Petfood, Unilever, Electronic Arts, Sony, Nokia, Adidas, Miele, Eurostar, MerckSerono, HP, Canon, Epson, Brother, P&G Airwave and Green-works. As a result, the division has a strong pipeline of committed work into the second half of the year, which will more than offset the expected decline in public sector work.

 

Tangible, Cello's response communications business, as expected, saw slight like for like decline in operating income in the first half. The income decline largely occurred due to certain public sector clients not repeating their programmes in 2010.

 

The business now operates out of three office hubs in Edinburgh, London and Cheltenham which is yielding both clear cost benefits, as well as professional and client benefits. A major cost reduction exercise was also undertaken last year, which with these structural changes, mean that operating margins in the current financial year have been substantially protected.

 

There has been a good series of major client wins by Tangible including Scottish and Southern Energy, Sainsbury's Bank, Reckitt Benckiser, O2, Chartis, SPX, SQA. Macmillan Cancer Care, The Sun (Scottish), Avon, Pfizer, Ben & Jerrys, Nandos and Matalan. The benefit of many of these wins will be seen in the second half of the year.

 

Given Tangible's strong flow of private sector client wins, and a more efficient cost base, the Group is confident that Tangible will be substantially ahead of 2009 on a full year basis.

Full year outlook

 

Revenue visibility for the next quarter remains solid and, subject to proper conversion of existing client opportunities, the Board is optimistic for a good full year outcome.

 

Mark Scott, Cello Chief Executive, commented:

 

 "We are pleased with our trading performance and like for like income growth levels in the first half of the year. We are seeing the benefits from our international investment programme initiated two years ago.

 

"The continued growth of income from our long term multi-national blue chip client base, both in the UK and internationally, has more than offset the expected weaker performance from our UK public sector clients. We are set well for the remainder of the year.

 

"Separately I am also delighted to welcome Paul Walton to the Board. As a senior client advisor and strategist, he will undoubtedly continue to make a substantial contribution across the Group"

 

The Group expects to publish its interim results on Tuesday 14 September 2010.

 

Enquiries:

 

Cello Group

020 7812 8460

Mark Scott, Chief Executive

Mark Bentley, Finance Director

Altium

020 7484 4040

Ben Thorne

Paul Chamberlain

College Hill

020 7457 2020

Adrian Duffield/Rozi Morris

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTEAKXFAFFEEFF
Date   Source Headline
5th Jun 20181:24 pmRNSBlock listing Interim Review
29th May 20183:45 pmRNSDirector/PDMR Dealings and Total Voting Rights
9th May 20181:14 pmRNSResult of AGM
9th May 20187:00 amRNSAGM Statement
30th Apr 20182:58 pmRNSTotal Voting Rights
26th Apr 20189:45 amRNSChange of Name
25th Apr 20184:45 pmRNSChange of Name update
23rd Apr 201810:28 amRNSChange of name to Cello Health Group plc
16th Apr 20189:30 amRNSAnnual Report and Notice of AGM
22nd Mar 20187:00 amRNSFinal Results
27th Feb 20183:38 pmRNSTotal Voting Rights
18th Jan 20187:00 amRNSPre Close Trading Statement
23rd Nov 20173:54 pmRNSHolding(s) in Company
31st Oct 201711:16 amRNSTotal Voting Rights
26th Oct 20172:37 pmRNSDirector/PDMR Shareholding
29th Sep 20173:43 pmRNSGrant of Options
27th Sep 20174:59 pmRNSDirector/PDMR Shareholding
22nd Sep 201712:05 pmRNSDirector/PDMR Shareholding
20th Sep 20173:58 pmRNSHolding(s) in Company
20th Sep 201711:52 amRNSAdditional Block Listing of Ordinary Shares
20th Sep 20177:00 amRNSInterim Results
31st Aug 20173:19 pmRNSTotal Voting Rights
31st Jul 20173:06 pmRNSTotal Voting Rights
19th Jul 20177:00 amRNSPre Close Trading Statement
18th Jul 20177:00 amRNSAcquisition of Advantage Healthcare Inc
30th Jun 201712:31 pmRNSTotal Voting Rights
23rd Jun 201712:23 pmRNSHolding(s) in Company
14th Jun 201711:33 amRNSDirector/PDMR Shareholding
31st May 201710:27 amRNSTotal Voting Rights
18th May 20172:13 pmRNSHolding(s) in Company
10th May 20175:18 pmRNSHolding(s) in Company
9th May 20172:55 pmRNSResult of AGM
9th May 20177:00 amRNSAGM Statement
2nd May 20173:15 pmRNSIssue of Equity
13th Apr 20172:40 pmRNSAnnual Report and notice of Annual General Meeting
4th Apr 20175:44 pmRNSBlock listing Interim Review
31st Mar 201710:43 amRNSTotal Voting Rights
28th Mar 20173:03 pmRNSHolding(s) in Company
22nd Mar 20177:00 amRNSPreliminary Results
21st Feb 20171:30 pmRNSHolding(s) in Company
20th Feb 20173:19 pmRNSHolding(s) in Company
20th Feb 20179:29 amRNSTotal Voting Rights
17th Feb 201710:40 amRNSResult of General Meeting
1st Feb 20177:00 amRNSPlacing & Acquisition of Defined Health
19th Jan 20177:00 amRNSPre close trading statement
31st Oct 20163:58 pmRNSTotal Voting Rights
28th Oct 201611:37 amRNSDirector/PDMR Shareholding
12th Oct 20167:00 amRNSDirectorate Change
5th Oct 20164:32 pmRNSDirector/PDMR Shareholding
23rd Sep 20165:30 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.